707 related articles for article (PubMed ID: 33280027)
21. Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes.
Lerma EV; Wilson DJ
Expert Rev Clin Pharmacol; 2022 May; 15(5):501-513. PubMed ID: 35762406
[TBL] [Abstract][Full Text] [Related]
22. [Mineralocorticoid receptor antagonists: A new therapeutic option for diabetic kidney disease].
Girerd S; Soulie M; Barrera-Chimal J; Jaisser F
Med Sci (Paris); 2023 Apr; 39(4):335-343. PubMed ID: 37094266
[TBL] [Abstract][Full Text] [Related]
23. Finerenone - are we there yet with a non-steroidal mineralocorticoid receptor antagonist for the treatment of diabetic chronic kidney disease?
Doggrell SA
Expert Opin Pharmacother; 2021 Jul; 22(10):1253-1256. PubMed ID: 33764251
[No Abstract] [Full Text] [Related]
24. Finerenone: First Approval.
Frampton JE
Drugs; 2021 Oct; 81(15):1787-1794. PubMed ID: 34519996
[TBL] [Abstract][Full Text] [Related]
25. Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes.
Ruilope LM; Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Sarafidis P; Schmieder RE; Joseph A; Rethemeier N; Nowack C; Bakris GL;
Hypertension; 2022 Dec; 79(12):2685-2695. PubMed ID: 36252131
[TBL] [Abstract][Full Text] [Related]
26. [Finerenone (Kerendia®), a new weapon against the chronic kidney disease of a patient with type 2 diabetes].
Scheen A; Delanaye P
Rev Med Liege; 2023 Dec; 78(12):725-732. PubMed ID: 38095038
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
Marzolla V; Infante M; Armani A; Rizzo M; Caprio M
Expert Opin Drug Saf; 2022 Sep; 21(9):1161-1170. PubMed ID: 36174659
[TBL] [Abstract][Full Text] [Related]
28. Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems.
Kolkhof P; Lawatscheck R; Filippatos G; Bakris GL
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012508
[TBL] [Abstract][Full Text] [Related]
29. Mineralocorticoid Antagonism and Diabetic Kidney Disease.
Lytvyn Y; Godoy LC; Scholtes RA; van Raalte DH; Cherney DZ
Curr Diab Rep; 2019 Jan; 19(1):4. PubMed ID: 30673886
[TBL] [Abstract][Full Text] [Related]
30. Finerenone: A Non-steroidal Mineralocorticoid Receptor Blocker for Diabetic Kidney Disease.
Verma A; Patel AB
Trends Endocrinol Metab; 2021 May; 32(5):261-263. PubMed ID: 33637415
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular and Renal Benefit of Novel Non-steroidal Mineralocorticoid Antagonists in Patients with Diabetes.
Kintscher U
Curr Cardiol Rep; 2023 Dec; 25(12):1859-1864. PubMed ID: 37991625
[TBL] [Abstract][Full Text] [Related]
32. Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR).
Tanaka A; Shibata H; Imai T; Yoshida H; Miyazono M; Takahashi N; Fukuda D; Okada Y; Teragawa H; Suwa S; Kida K; Moroi M; Taguchi I; Toyoda S; Shimabukuro M; Tanabe K; Tanaka K; Nangaku M; Node K;
Cardiovasc Diabetol; 2023 Jul; 22(1):194. PubMed ID: 37525257
[TBL] [Abstract][Full Text] [Related]
33. Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study.
Ruilope LM; Pitt B; Anker SD; Rossing P; Kovesdy CP; Pecoits-Filho R; Pergola P; Joseph A; Lage A; Mentenich N; Scheerer MF; Bakris GL
Nephrol Dial Transplant; 2023 Feb; 38(2):372-383. PubMed ID: 35451488
[TBL] [Abstract][Full Text] [Related]
34. The Nonsteroidal Mineralocorticoid-Receptor-Antagonist Finerenone in Cardiorenal Medicine: A State-of-the-Art Review of the Literature.
Georgianos PI; Agarwal R
Am J Hypertens; 2023 Feb; 36(3):135-143. PubMed ID: 36331811
[TBL] [Abstract][Full Text] [Related]
35. The Role of the Non-Steroidal Mineralocorticoid Antagonist Finerenone in Cardiorenal Management.
Beavers CJ
Curr Cardiol Rep; 2022 Dec; 24(12):1785-1790. PubMed ID: 36272052
[TBL] [Abstract][Full Text] [Related]
36. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
Wish JB; Pergola P
Mayo Clin Proc Innov Qual Outcomes; 2022 Dec; 6(6):536-551. PubMed ID: 36277502
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD.
Eissing T; Goulooze SC; van den Berg P; van Noort M; Ruppert M; Snelder N; Garmann D; Lippert J; Heinig R; Brinker M; Heerspink HJL
Diabetes Obes Metab; 2024 Mar; 26(3):924-936. PubMed ID: 38037539
[TBL] [Abstract][Full Text] [Related]
38. Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease.
Filippatos G; Anker SD; Pitt B; McGuire DK; Rossing P; Ruilope LM; Butler J; Jankowska EA; Michos ED; Farmakis D; Farjat AE; Kolkhof P; Scalise A; Joseph A; Bakris GL; Agarwal R
Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 9(1):85-93. PubMed ID: 36251465
[TBL] [Abstract][Full Text] [Related]
39. Optimization of potassium management in patients with chronic kidney disease and type 2 diabetes on finerenone.
Ortiz A; Alcázar Arroyo R; Casado Escribano PP; Fernández-Fernández B; Martínez Debén F; Mediavilla JD; Michan-Doña A; Soler MJ; Gorriz JL
Expert Rev Clin Pharmacol; 2023; 16(6):519-531. PubMed ID: 37190957
[TBL] [Abstract][Full Text] [Related]
40. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
Pandey AK; Bhatt DL; Cosentino F; Marx N; Rotstein O; Pitt B; Pandey A; Butler J; Verma S
Eur Heart J; 2022 Aug; 43(31):2931-2945. PubMed ID: 35713973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
